TMDX Insider Trading

Insider Ownership Percentage: 7.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $44,144,709.16

TransMedics Group Insider Trading History Chart

This chart shows the insider buying and selling history at TransMedics Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M$0$20MTotal Insider BuyingTotal Insider Selling

TransMedics Group Share Price & Price History

Current Price: $70.96
Price Change: Price Decrease of -2.15 (-2.94%)
As of 04/3/2025 05:00 PM ET

This chart shows the closing price history over time for TMDX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$70.96Closing price on 04/03/25:

SEC Filings (Institutional Ownership Changes) for TransMedics Group (NASDAQ:TMDX)

99.67% of TransMedics Group stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TMDX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$376Mbought$1.13BsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1B-$500M$0$500M$1BTotal InflowsTotal Outflows
TransMedics Group logo
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Read More on TransMedics Group

Today's Range

Now: $70.96
Low: $68.00
High: $71.72

50 Day Range

MA: $69.93
Low: $60.82
High: $79.42

52 Week Range

Now: $70.96
Low: $55.00
High: $177.37

Volume

1,116,562 shs

Average Volume

1,323,015 shs

Market Capitalization

$2.39 billion

P/E Ratio

75.49

Dividend Yield

N/A

Beta

2.12

Who are the company insiders with the largest holdings of TransMedics Group?

TransMedics Group's top insider investors include:
  1. Waleed H Hassanein (CEO)
  2. James R Tobin (Director)
  3. Tamer I Khayal (Insider)
  4. Stephen Gordon (CFO)
  5. Miriam Provost (VP)
  6. Nicholas Corcoran (Insider)
  7. David Weill (Director)
  8. Anil P Ranganath (Insider)
  9. Edward M Basile (Director)
Learn More about top insider investors at TransMedics Group.